Skip to main content

Bone Cancer clinical trials at UC Davis
3 research studies open to eligible people

  • A Study Comparing Experimental Antibiotic Therapies in Tumor Surgery (PARITY Study)

    open to eligible people ages 12 years and up

    The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial is the first ever international multi-center randomized controlled trial in bone cancer surgery. In order to avoid amputation for bone cancer in the leg, complex limb-saving operations are performed. However, infections with devastating complications following surgery are common. Surgeons from across the world will randomize patients to receive either short- or long-duration antibiotic regimens after surgery with the goal of identifying the best regimen to reduce these infections.

    San Francisco, California and other locations

  • A Study of the Effects of Chemotherapy on Fertility in Osteosarcoma (bone cancer) Survivors

    open to eligible males ages 18-50

    This research trial studies saliva, semen, and blood samples to determine effects of chemotherapy on fertility in osteosarcoma survivors. Study biospecimen samples from osteosarcoma survivors in the laboratory may help doctors learn whether chemotherapy causes fertility problems and to learn more about the long term effects.

    Sacramento, California and other locations

  • Study looking at targeted chemotherapy and immunotherapy in treating patients with advanced/metastatic genitourinary tumors

    “Targeted chemotherapy and immunotherapy medicine with or without additional immunotherapy medicine to treat bladder/urothelial cancer”

    open to eligible people ages 18 years and up

    This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread to other places in the body. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.

    Sacramento, California and other locations

Last updated: